B细胞成熟抗原在多发性骨髓瘤中的靶向治疗原理与当前治疗策略
多发性骨髓瘤(MM)仍无法治愈,患者最终耐药,亟需新机制疗法。B细胞成熟抗原(BCMA)在MM中过表达且具预后价值,可作为治疗靶点。本文综述靶向BCMA的双特异性抗体、抗体药物偶联物和CAR-T疗法,初步临床数据显示显著抗骨髓瘤活性和高微小残留病阴性率。
要点
- BCMA在MM中过表达,支持其作为治疗靶点。
- 靶向BCMA的三种主要模式:双特异性抗体、ADC和CAR-T。
- 初步临床显示深度持久缓解,支持早期治疗探索。
核心结论
- 靶向BCMA的双特异性抗体、抗体药物偶联物和CAR-T疗法在多发性骨髓瘤中展现出显著抗骨髓瘤活性和高微小残留病阴性率。
研究设计与样本
- 综述类文章,汇总靶向BCMA治疗多发性骨髓瘤的临床前与临床研究数据。
主要发现
- 多种BCMA靶向治疗观察到显著抗骨髓瘤活性和高微小残留病阴性率。
关键数值与推荐
- 涉及的治疗包括BiTE免疫肿瘤疗法AMG 420、抗体药物偶联物GSK2857916以及CAR-T细胞疗法bb2121、NIH CAR-BCMA和LCAR-B38M。
临床怎么用
- BCMA靶向疗法有望提供深度持久缓解,支持在新诊断MM等早期治疗线中进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there is no cure for MM, patients eventually become resistant to therapies, leading to development of relapsed/refractory MM. Therefore, an unmet need exists for MM treatments with novel mechanisms of action that can provide durable responses, evade resistance to prior therapies, and/or are better tolerated. B-cell maturation antigen (BCMA) is preferentially expressed by mature B lymphocytes, and its overexpression and activation are associated with MM in preclinical models and humans, supporting its potential utility as a therapeutic target for MM. Moreover, the use of BCMA as a biomarker for MM is supported by its prognostic value, correlation with clinical status, and its ability to be used in traditionally difficult-to-monitor patient populations. Here, we review three common treatment modalities used to target BCMA in the treatment of MM: bispecific antibody constructs, antibody-drug conjugates, and chimeric antigen receptor (CAR)-modified T-cell therapy. We provide an overview of preliminary clinical data from trials using these therapies, including the BiTE® (bispecific T-cell engager) immuno-oncology therapy AMG 420, the antibody-drug conjugate GSK2857916, and several CAR T-cell therapeutic agents including bb2121, NIH CAR-BCMA, and LCAR-B38M. Notable antimyeloma activity and high minimal residual disease negativity rates have been observed with several of these treatments. These clinical data outline the potential for BCMA-targeted therapies to improve the treatment landscape for MM. Importantly, clinical results to date suggest that these therapies may hold promise for deep and durable responses and support further investigation in earlier lines of treatment, including newly diagnosed MM.
引用
- Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020. PMID: 32055000. doi:10.1038/s41375-020-0734-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。